Frequent Early Cardiac Complications Contribute to Worse Stroke Outcome in Atrial Fibrillation
Hans TH Tu, Bruce CV Campbell, Leonid Churilov, Jonathan M Kalman, Kennedy R Lees, Patrick D Lyden, Ashfaq Shuaib, Geoffrey A Donnan, Stephen M Davis
Cerebrovascular Diseases | KARGER | Published : 2011
Awarded by Medical Research Council
Awarded by Chief Scientist Office
This study received funding from The Royal Melbourne Hospital Neuroscience Foundation.H.T.H. Tu, B. C. V. Campbell, L. Churilov and J.M. Kalman report no relevant disclosures. K. R. Lees has received honoraria from Astellas, Asubio, Bayer, Boehringer Ingelheim, Johnson & Johnson, Lundbeck, Mitsubishi, Photothera, Sanofi-Aventis, Servier, Talecris, and Wyeth. P. D. Lyden receives royalties from sale of the book Thrombolytic Therapy for Acute Stroke. A. Shuaib has received honoraria and research grants from Astra Zeneca, Boehringer Ingelheim, Pfizer, Roche, Bayer, Coaxia, and Photothera. G. A. Donnan has served on advisory boards for Boehringer Ingelheim, Servier, Sanofi-Aventis and Bristol Myers Squibb. S. M. Davis has served on advisory Boards for Boehringer Ingelheim, Ever Pharma, Pfizer and Sanofi-Aventis.